Oxford Expression Technologies

Executive Summary

Oxford Expression Technologies (OET) is a UK-based biotechnology company specializing in recombinant protein production using its proprietary flashBAC™ baculovirus expression system. With over two decades of experience, OET has established itself as a world-leading center of excellence in this niche, offering products, services, and consultancy to the global pharmaceutical and biotech industries. The company is actively expanding into mammalian and bacterial expression systems, positioning itself to address a broader range of biomanufacturing needs. Additionally, OET is engaged in grant-funded vaccine development projects, leveraging its expertise to contribute to infectious disease research. The company's proven technology and customer base provide a solid foundation for growth, though its private status limits visibility into financials and market traction.

Upcoming Catalysts (preview)

• TBDNew grant-funded vaccine development milestone75% success
• TBDExpansion into mammalian expression system partnership60% success
• TBDPotential new funding round or strategic investment50% success